Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MPI 5003

Drug Profile

MPI 5003

Alternative Names: AccuSite; Fluorouracil/epinephrine injectable gel

Latest Information Update: 24 Jun 1999

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiron Corporation
  • Developer ALTANA Group; Chiron Corporation; Dompe; Savage Laboratories
  • Class
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Human papillomavirus infections
  • Discontinued Basal cell cancer; Kaposi's sarcoma; Psoriasis; Squamous cell cancer

Most Recent Events

  • 24 Jun 1999 Discontinued-II for Kaposi's sarcoma in United Kingdom (Intralesional)
  • 24 Jun 1999 Discontinued-II for Squamous cell cancer in Australia (Intralesional)
  • 24 Jun 1999 Discontinued-II for Squamous cell cancer in USA (Intralesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top